Selling MGM March 16 calls out of my Volatility Portfolio
Shares of MGM Resorts International (MGM) rose 2.52% on Friday, February 23, to close at $35.38. I'm going to use that move to the upside to sell my March 16, 2018 MGM calls (MGM180316C00033000) out of my Volatility Portfolio. I bought these options back on September...
To rebalance my Volatility Portfolio I’m selling my Nektar May 18 call options
I'm not complaining, mind you. As of Friday February 23, the Nektar Therapeutics May 18, 2018 call options with a strike of $26 (NKTR180518C00026000) in my Volatility Portfolio were up 2546% from my November 1, 2017 buy at $2.40 to $63.50. But I don't want to have...
Big earnings report from MGM Resorts before the market open tomorrow
Tomorrow's earnings report from MGM Resorts International (MGM) could be make or break for the call options that I hold on this stock in my Volatility Portfolio. The options have been all over the block in recent weeks from up 50% to down 30% on market volatility and...
How to use my portfolios
We’ve had a big influx of new readers here at JubakAM.com thanks to the magic of groundhogs and our Groundhog Day 20% off deal. And I’ve received a number of questions that boil down to How do I get started using the five portfolios on the site? Here’s my advice.
Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug
In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate still in trials and that has shown the ability to extend the range of Bristol-Myers Opdivo
Adding an ETF to short Treasuries to my Volatility Portfolio
As I write this at 3:50 p.m. New York time, the Dow Jones Industrial Average is down 646 points or 2.47%. The Standard & Poor's 500 Stock Index is off 1.92% or 54.32 points. The NASDAQ Composite is down 1.89% and the Russell 2000 small cap index is lower by 1.72%....
Volatility Portfolio up 53% in 2017
When I started my Volatility Portfolio back in January 2017, I really didn’t have much more in mind than a conviction that in this market traders and investors and traders could score market beating returns from taking advantage of market and economic volatility. I didn’t narrow my approach to volatility to one or two aspects or markets, but instead followed a wide menu approach to volatility as a characteristic stretching across markets from real estate to bonds to education to stocks. That menu as based on the research I’d done for my February 2016 book Juggling with Knives: Smart Investing in the Coming Age of Volatility. Certainly the return on this portfolio for its first year of operation confirm this wide-menu approach. The portfolio showed a total return of 53.06%–assuming equal initial weightings in each position–as of December 31, 2017. That qualifies, I’d say, as beating the market in 2017. The total return on the Standard & Poor’s 500 stock index was 21.64% in 2017. But in that first year of operation I found a more focused goal for the Volatility Portfolio too.
Gold keeps climbing on rising demand from ETFs
Gold held by ETFs that invest in the yellow metal rose to 2,250 metric tons on January 22, according to Bloomberg. That’s the highest level of gold held by ETFs since May 2013. After turning in its best year since 2010 in 2017, gold has continued to climb in 2018
Nektar soars today on J.P. Morgan healthcare conference
Anybody still think that conferences, especially biotech conferences, don’t move stock prices? Shares of Nektar Therapeutics (NKTR) are up 7.65% today to $61.79 as of noon New York time on the company’s appearance at this week’s J.P. Morgan biotech conference. The slides from the company’s presentation today are in circulation but CEO Howard Robin doesn’t actually present until 2 p.m. New York time today.
Adding shares of First Quantum to my Volatility Portfolio as a long-dated option on copper
When, way back on August 17, I started recommending going long copper on the increasing adoption of electric cars, I noted that the big uncertainty in this play was how fast demand for electric vehicles and charging stations would grow. Electric cars use more copper...
On the second day of Christmas my stock pick for 2018 is Nektar Therapeutics–and two-turtle doves
No point in hoping that Nektar Therapeutics (NKTR) will match this year's gain of 364% as of the close on December 18. But I think the stock could easily climb another 30% or more in 2018 as the company de-risks its very promising drug candidates in the opioid and...Jim’s Stock Alerts
Download Jim’s eBook for Free
